Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction: results from the EMPULSE trial
Aim The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium-glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF)....
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2024
|
| In: |
European journal of heart failure
Year: 2024, Volume: 26, Issue: 4, Pages: 963-970 |
| ISSN: | 1879-0844 |
| DOI: | 10.1002/ejhf.3218 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ejhf.3218 Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.3218 
|
| Author Notes: | Jasper Tromp, Mikhail N. Kosiborod, Christiane E. Angermann, Sean P. Collins, John R. Teerlink, Piotr Ponikowski, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Martina Brueckmann, Jonathan P Blatchford, Dominik Steubl, and Adriaan A. Voors |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 191619589X | ||
| 003 | DE-627 | ||
| 005 | 20250716225958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.3218 |2 doi | |
| 035 | |a (DE-627)191619589X | ||
| 035 | |a (DE-599)KXP191619589X | ||
| 035 | |a (OCoLC)1528018409 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Tromp, Jasper |e VerfasserIn |0 (DE-588)1355122937 |0 (DE-627)1916196829 |4 aut | |
| 245 | 1 | 0 | |a Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction |b results from the EMPULSE trial |c Jasper Tromp, Mikhail N. Kosiborod, Christiane E. Angermann, Sean P. Collins, John R. Teerlink, Piotr Ponikowski, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Martina Brueckmann, Jonathan P Blatchford, Dominik Steubl, and Adriaan A. Voors |
| 264 | 1 | |c April 2024 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Erstmals veröffentlicht: 04. April 2024 | ||
| 500 | |a Gesehen am 03.02.2025 | ||
| 520 | |a Aim The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium-glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF). We investigated whether efficacy and safety of empagliflozin were consistent across the spectrum of left ventricular ejection fraction (LVEF). Methods and results A total of 530 patients hospitalized for acute de novo or decompensated HF were included irrespective of LVEF. For the present analysis, patients were classified as HF with reduced (HFrEF, LVEF ≤40%), mildly reduced (HFmrEF, LVEF 41-49%) or preserved (HFpEF, LVEF ≥50%) ejection fraction at baseline. The primary endpoint was a hierarchical outcome of death, worsening HF events (HFE) and quality of life over 90 days, assessed by the win ratio. Secondary endpoints included individual components of the primary endpoint and safety. Out of 523 patients with baseline data, 354 (67.7%) had HFrEF, 54 (10.3%) had HFmrEF and 115 (22.0%) had HFpEF. The clinical benefit (hierarchical composite of all-cause death, HFE and Kansas City Cardiomyopathy Questionnaire total symptom score) of empagliflozin at 90 days compared to placebo was consistent across LVEF categories (≤40%: win ratio 1.35 [95% confidence interval 1.04, 1.75]; 41-49%: win ratio 1.25 [0.66, 2.37)] and ≥50%: win ratio 1.40 [0.87, 2.23], pinteraction = 0.96) with a favourable safety profile. Results were consistent across individual components of the hierarchical primary endpoint. Conclusion The clinical benefit of empagliflozin proved consistent across LVEF categories in the EMPULSE trial. These results support early in-hospital initiation of empagliflozin regardless of LVEF. | ||
| 650 | 4 | |a Acute heart failure | |
| 650 | 4 | |a Left ventricular ejection fraction | |
| 650 | 4 | |a SGLT2 inhibitor | |
| 700 | 1 | |a Kosiborod, Mikhail N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Angermann, Christiane E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Collins, Sean P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Teerlink, John R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Biegus, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nassif, Michael E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Psotka, Mitchell A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Blatchford, Jonathan P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steubl, Dominik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Voors, Adriaan A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d Oxford : Wiley, 1999 |g 26(2024), 4 vom: Apr., Seite 963-970 |h Online-Ressource |w (DE-627)306658291 |w (DE-600)1500332-2 |w (DE-576)081985983 |x 1879-0844 |7 nnas |a Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:4 |g month:04 |g pages:963-970 |g extent:8 |a Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ejhf.3218 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.3218 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250203 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 11 | ||
| 999 | |a KXP-PPN191619589X |e 4660066401 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"April 2024"}],"name":{"displayForm":["Jasper Tromp, Mikhail N. Kosiborod, Christiane E. Angermann, Sean P. Collins, John R. Teerlink, Piotr Ponikowski, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Martina Brueckmann, Jonathan P Blatchford, Dominik Steubl, and Adriaan A. Voors"]},"relHost":[{"part":{"volume":"26","pages":"963-970","year":"2024","text":"26(2024), 4 vom: Apr., Seite 963-970","issue":"4","extent":"8"},"disp":"Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trialEuropean journal of heart failure","pubHistory":["1.1999 -"],"origin":[{"publisher":"Oxford University Press ; Elsevier Science ; Oxford Univ. Press ; Wiley","dateIssuedDisp":"1999-","publisherPlace":"Oxford ; Amsterdam [u.a.] ; Oxford [u.a.] ; Oxford","dateIssuedKey":"1999"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"subtitle":"journal of the Working Group on Heart Failure of the European Society of Cardiology","title":"European journal of heart failure","title_sort":"European journal of heart failure"}],"note":["Gesehen am 07.01.25"],"titleAlt":[{"title":"EJHF"}],"recId":"306658291","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"doi":["10.1002/(ISSN)1879-0844"],"eki":["306658291"],"zdb":["1500332-2"],"issn":["1879-0844"]}}],"recId":"191619589X","id":{"doi":["10.1002/ejhf.3218"],"eki":["191619589X"]},"language":["eng"],"physDesc":[{"extent":"8 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Erstmals veröffentlicht: 04. April 2024","Gesehen am 03.02.2025"],"person":[{"given":"Jasper","role":"aut","roleDisplay":"VerfasserIn","family":"Tromp","display":"Tromp, Jasper"},{"roleDisplay":"VerfasserIn","family":"Kosiborod","display":"Kosiborod, Mikhail N.","given":"Mikhail N.","role":"aut"},{"display":"Angermann, Christiane E.","family":"Angermann","roleDisplay":"VerfasserIn","given":"Christiane E.","role":"aut"},{"role":"aut","given":"Sean P.","family":"Collins","display":"Collins, Sean P.","roleDisplay":"VerfasserIn"},{"given":"John R.","role":"aut","display":"Teerlink, John R.","family":"Teerlink","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Ponikowski, Piotr","family":"Ponikowski","given":"Piotr","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Biegus, Jan","family":"Biegus","given":"Jan","role":"aut"},{"given":"João Pedro","role":"aut","display":"Ferreira, João Pedro","family":"Ferreira","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Michael E.","family":"Nassif","display":"Nassif, Michael E.","roleDisplay":"VerfasserIn"},{"display":"Psotka, Mitchell A.","family":"Psotka","roleDisplay":"VerfasserIn","role":"aut","given":"Mitchell A."},{"role":"aut","given":"Martina","roleDisplay":"VerfasserIn","family":"Brückmann","display":"Brückmann, Martina"},{"given":"Jonathan P","role":"aut","roleDisplay":"VerfasserIn","family":"Blatchford","display":"Blatchford, Jonathan P"},{"family":"Steubl","display":"Steubl, Dominik","roleDisplay":"VerfasserIn","given":"Dominik","role":"aut"},{"display":"Voors, Adriaan A.","family":"Voors","roleDisplay":"VerfasserIn","given":"Adriaan A.","role":"aut"}],"title":[{"subtitle":"results from the EMPULSE trial","title":"Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction","title_sort":"Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction"}]} | ||
| SRT | |a TROMPJASPETREATMENTE2024 | ||